Contact Information:

Media Contact

Iga Rawicka
irawicka@sirtex.com

http://www.sirtex.com




Kredyty mieszkaniowe Kredyty mieszkaniowe

Sprawdź aktualny ranking najlepszych kredytów mieszkaniowych w Polsce - atrakcyjne kredytowanie nieruchomości.

PRESS-NEWS.org - Press Release Distribution
FREE PRESS RELEASES DISTRIBUTION
RSS - Press News Release
Add Press Release

SIRFLOX study presented at ASCO 2015 Annual Meeting


2015-06-01
(Press-News.org) Chicago, IL, USA (30 May 2015) -- The benefits of adding liver-directed SIR-Spheres Y-90 resin microspheres to a current systemic chemotherapy for the first-line treatment of unresectable metastatic colorectal cancer (mCRC) reported in the SIRFLOX study, were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The results of the 530-patient SIRFLOX randomized controlled study, which open new possibilities for combining radiation targeted at liver metastases with first-line systemic treatment of mCRC, were presented by Associate Professor Peter Gibbs, co-principal investigator of the SIRFLOX study and Consultant Medical Oncologist, The Royal Melbourne Hospital, Australia.

"We found that while liver tumours began to grow again after a median of 12.6 months in patients with mCRC who received only first-line chemotherapy, those who also received first-line treatment with SIR-Spheres Y-90 resin microspheres had their liver tumours controlled for a median of 20.5 months. The additional 7.9 months of treatment benefit with the combined first-line SIRFLOX regimen was statistically significant, with a p-value of 0.002 and a hazard ratio of 0.69. This translates to a 31 percent reduction in the risk of tumour progression in the liver for patients treated with Y-90 resin microspheres," Prof. Gibbs said.

"This finding matters a great deal," he explained, "because the liver is almost invariably the organ where colorectal cancer spreads to first. While half the patients initially diagnosed with colorectal cancer survive thanks to surgical removal of the primary tumour before the disease has spread elsewhere in the body, liver metastases eventually cause the death of the majority of the remaining hundreds of thousands of patients each year whose tumours spread but are inoperable."

Prof. Gibbs also told the ASCO audience that liver treatment response rates were significantly higher in patients who received Y-90 resin microspheres in combination with first-line chemotherapy, which consisted of a FOLFOX-based regimen, with or without the addition of bevacizumab. "We observed a hepatic response rate of 78.7 percent in this group, compared to 68.8 percent in the chemotherapy-only group. This was statistically significant, with a p-value of 0.042. Moreover, the rate of complete responses in the liver of SIRFLOX patients who received SIR-Spheres Y-90 resin microspheres, though relatively small at 6.0 percent, was more than three times higher than the 1.9 percent complete response rate among the chemotherapy-only patients. The statistical significance of this finding is very strong, with a p-value of 0.02," Prof. Gibbs stated.

Other SIRFLOX Clinical Investigators Discuss Study Implications

At a press conference following Prof. Gibbs's SIRFLOX presentation, Prof. Guy van Hazel, co-principal investigator of SIRFLOX and Clinical Professor of Medicine at the University of Western Australia, Perth, said that "SIRFLOX gives us the data to validate the first-line use of selective internal radiation therapy, or SIRT, with SIR-Spheres Y-90 resin microspheres in mCRC. Until now, we have not had a randomized clinical study large enough to provide Level One evidence supporting first-line use of this treatment."

"This step forward matters to medical oncologists and their patients, because until the development of Y-90 resin microspheres, there was essentially no place for radiation therapy in the treatment of liver tumours. There was never a question that radiation would work in the liver, but the problem of administering the radiation in a way that spared healthy liver tissue from its effects prevented it from being an 'equal partner' with surgery and chemotherapy in treating mCRC, as it is in almost all other forms of cancer," Prof. van Hazel added.

The principal European investigator of SIRFLOX, Prof. Volker Heinemann, Director of the Comprehensive Cancer Center at the University of Munich, Germany, told the press conference audience that, "Medical oncologists, particularly also at the community level, are only now beginning to recognize that treating liver metastases locally as well as systemically is a very important clinical consideration in the effective management of this difficult-to-treat cancer, and may also open up the possibility of potentially curative liver surgery in some previously unresectable cases."

"The effect of Y-90 resin microspheres on Progression-Free Survival in the liver, as reported in the SIRFLOX study, is quite pronounced," Prof. Heinemann continued. "Even in the absence of sufficient data to calculate an overall survival benefit or a significant finding for the primary endpoint of Progression-Free Survival at any site, the outcome of SIRFLOX suggests that oncologists who treat mCRC may now wish to consider earlier use of Y-90 resin microspheres than is presently the case, certainly among those patients whose metastatic disease has been diagnosed primarily in the liver."

"With SIRFLOX, the Level One evidence is there for every medical oncologist to see and to evaluate in their practice," he said.

The principal U.S. investigator of SIRFLOX, Dr. Navesh K. Sharma, Assistant Professor of Radiation Oncology and Diagnostic/Interventional Radiology at the University of Maryland Medical Center, which was the largest US clinical site for SIRFLOX, said that, "With 530 patients, SIRFLOX is the largest randomized trial ever conducted that combined an interventional radiology procedure with chemotherapy in oncology."

"Physicians have been performing SIRT procedures with Y-90 resin microspheres, in the US and around the world, for more than 10 years. We have always felt that this procedure was a unique approach to deliver large doses of radiation to liver tumours, targeted in a way that spares healthy liver tissue. It is important to observe that in SIRFLOX, the clinical benefit that was observed came with an acceptable level of adverse events from adding Y-90 resin microspheres to first-line chemotherapy in mCRC. Oncologists, especially radiation oncologists, have traditionally been very cautious of irradiating large liver volumes because of the adverse effects associated with such treatments. SIRFLOX has shown us, in an unbiased manner that not only can we deliver high doses of radiation to the liver safely with this approach, but we can do so using concurrent chemotherapy. Concurrent chemo-radiation has been one of the most effective ways to treat cancer in general, especially those of gastrointestinal origin," Dr. Sharma said.

In a further indication of the potential clinical relevance of the combined chemo-radiation regimen studied in SIRFLOX, ASCO has selected the SIRFLOX study results as one of just 71 of the several thousand abstracts reviewed for this meeting as a "Best of ASCO" presentation. "Best of ASCO" papers may be discussed in an ongoing cascade of official follow-up presentations that national oncology leaders will deliver over the coming months to medical oncologists in their countries who were unable to attend the ASCO Congress in Chicago.

SIRFLOX is the first of a group of three studies assessing the results of adding SIR-Spheres Y-90 resin microspheres to first-line chemotherapy in the treatment of mCRC. The other studies are FOXFIRE, a UK clinical trial that completed enrolment in November 2014, and FOXFIRE Global, an international study that completed enrolment in January 2015. The results of the three studies, which together enrolled more than 1,100 mCRC patients, will be combined in a pre-planned assessment of the overall survival benefit of adding SIR-Spheres Y-90 resin microspheres to first-line chemotherapy for mCRC. The combined results are expected in 2017.

The co-principal investigators of FOXFIRE are Professor Ricky Sharma, Clinical Senior Lecturer in Oncology at the University of Oxford, UK, and Dr. Harpreet Wasan of Hammersmith Hospital and the Imperial College Trust, London, UK. Professor Sharma was also the discussant of SIRFLOX at the ASCO Annual Meeting in Chicago. Professor Peter Gibbs is the principal investigator of FOXFIRE Global.

INFORMATION:

About SIR-Spheres Y-90 Resin Microspheres

SIR-Spheres Y-90 resin microspheres are a medical device used in an interventional radiology procedure known as selective internal radiation (SIRT), or radioembolisation, which targets high doses of radiation directly to liver tumours. The treatment consists of tens of millions of radioactive Y-90 coated resin particles, each no bigger in diameter than a human hair. Interventional radiologists inject these resin particles, or microspheres, into the hepatic artery via a catheter inserted into the femoral artery through an incision in the groin. The Y-90 resin microspheres become lodged in the capillaries that surround liver tumours, where they deliver a high dose of short-range (mean 2.5 mm; maximum 11 mm) beta radiation to the liver tumours, while sparing health liver tissue. The low specific gravity of Y-90 resin microspheres allows the blood flow to evenly distribute the radioactivity within and around the liver tumours.

Key SIR-Spheres Y-90 resin microspheres regulatory authorisations include a full Pre-Market Approval from the US FDA, European Union (CE Mark) and Australian TGA Conformity Assessment certification.

SIR-Spheres Y-90 resin microspheres also have a Premarket Approval (PMA) by the FDA and are indicated in the United States for the treatment of non-resectable metastatic liver tumors from primary colorectal cancer in combination with intra-hepatic artery chemotherapy using floxuridine. SIR-Spheres Y-90 resin microspheres are approved for the treatment of inoperable liver tumors in Australia, the European Union (CE Mark), Argentina (ANMAT), Brazil, and several countries in Asia, such as India and Singapore.

About Sirtex

Sirtex Medical Limited (ASX:SRX) is an Australian-based global healthcare business working to improve treatment outcomes in people with cancer. Our current lead product is a targeted radiation therapy for liver cancer called SIR-Spheres Y-90 resin microspheres. Approximately 50,000 doses have been supplied to treat patients with liver cancer at more than 800 medical centres in over 40 countries.

For more information, please visit http://www.sirtex.com.

SIR-Spheres® is a Registered Trademark of Sirtex SIR-Spheres Pty Ltd

Reference: Gibbs P et al. 2015 ASCO Annual Meeting; J Clin Oncol 2015; 33 (Suppl): Abs 3502.

For more information, please contact:

Iga Rawicka; Sirtex Medical Limited; email: irawicka@sirtex.com

107-U-0515


ELSE PRESS RELEASES FROM THIS DATE:

PharmaMar's PM1183 plus doxorubicin shows remarkable activity in small cell lung cancer

2015-06-01
Chicago and Madrid, June 1st 2015: PharmaMar today announced data from a Phase 1b study of the transcriptional inhibitor PM1183 in combination with doxorubicin in second line therapy in patients with small cell lung cancer (SCLC) showing that the treatment induced objective responses in 67% of the patients, including 10% of them where all signs of cancer disappeared (complete responses). Every patient with SCLC denominated primary chemotherapy-sensitive (their chemotherapy-free interval (CTFI) is more than 90 days) responded to treatment, including 18% of complete responses. ...

Trabectedin shows activity in ATREUS trial in patients with sarcomatoid malignant mesothelioma

2015-06-01
Chicago and Madrid, June 1st 2015: PharmaMar today announced data from a Phase 2 study in patients with sarcomatoid/biphasic malignant pleural mesothelioma showing that 41.2% (95% CI: 18.4-67.1) of patients treated with the anticancer drug trabectedin in second line were alive and free of progression at 12 weeks. The median progression-free survival (PFS) in these 17 evaluated patients was 8.3 weeks. There were 5 patients who continue receiving trabectedin beyond 12 weeks. "Mesothelioma patients usually do not respond to second-line treatments so the preliminary data ...

Vitamin D and calcium supplements do not improve menopausal symptoms

2015-06-01
PORTLAND, Ore., June 01, 2015 -- Women who took vitamin D and calcium supplements had the same number of menopausal symptoms as women who did not take the supplements, according to a study published today in Maturitas, the official journal of the European Menopause and Andropause Society. The study, which involved 34,157 women ages 50-79, is part of the Women's Health Initiative, one of the largest clinical trials ever undertaken to address the most common causes of death, disability and impaired quality of life in menopausal women. "Our study suggests that women ...

Psychology: Does aging affect decision making?

2015-06-01
Aging is associated with significant decline in cognitive functions. But does this translate into poorer decision making? Psychologists from the University of Basel and the Max Planck Institute for Human Development report that in simple decision situations, older adults perform just as well as younger adults. However, according to their study published in the academic journal Cognition, aging may affect decision performance in more complex decision situations. Important decisions in politics and economics are often made by older people: According to Forbes magazine, ...

Resources for the seven day services may be better spent on other NHS priorities

2015-06-01
The NHS could achieve up to twice as much with the resources that the Government plans to spend introducing a full seven day service in the NHS in England, according to new research from The University of Manchester. Health economists, working with colleagues at the University of York, have used official data to suggest an extra 5,353 deaths each year occur when people are admitted to hospital at the weekend rather than mid-week, but that the £1.43 billion cost of removing this risk would be better spent on other priorities. Despite a seven day health service ...

Improving the experience of the audience with digital instruments

Improving the experience of the audience with digital instruments
2015-06-01
Researchers have developed a new augmented reality display that allows the audience to explore 3D augmentations of digital musical performances in order to improve their understanding of electronic musicians' engagement. The diversity of digital musical instruments keeps increasing, especially with the emergence of software and hardware that musicians can modify. While this diversity creates novel artistic possibilities, it also makes it more difficult for the audience to appreciate what the musicians are doing during performances. Contrary to acoustic instruments, digital ...

The less you sleep, the more you eat

2015-06-01
London, UK (1st June, 2015) - Factors influencing food intake have, and continue to be, a hotly contested subject. A new paper published today in the SAGE journal, Journal of Health Psychology (JHP), suggests that disrupted sleep could be one factor contributing to excessive food intake and thus leading to long term chronic health damage in both adults and children. In a special issue on Food, Diets, and Dieting, the paper explores how a bad night's sleep - something that affects millions of people worldwide - can affect eating habits and behaviors. Though it is well-known ...

Gut check: Does a hospital stay set patients up for sepsis by disrupting the microbiome?

2015-06-01
ANN ARBOR, Mich. - Can a routine hospital stay upset the balance of microbes in our bodies so much that it sets some older people up for a life-threatening health crisis called sepsis? A new University of Michigan and VA study suggests this may be the case. It shows that older adults are three times more likely to develop sepsis -- a body-wide catastrophic response to infection -- in the first three months after leaving a hospital than at any other time. What's more, the risk of sepsis in that short post-hospital time is 30 percent higher for people whose original hospital ...

Weakening memories of crime through deliberate suppression

2015-06-01
There are some bad memories -- whether of a crime or a painful life event -- that we'd rather not recall. New research shows that people can successfully inhibit some incriminating memories, reducing the memories' impact on automatic behaviors and resulting in brain activity similar to that seen in "innocent" participants. The research is published in Psychological Science, a journal of the Association for Psychological Science. "In real life, many individuals who take memory detection tests want to distort their results. Using a lab-based crime simulation, we examined ...

The fly's time

2015-06-01
This news release is available in French. The Drosophila, the so-called fruit fly, attends all day long to its activities. It flutters, has naps, lays its eggs or emerges from the pupa, the stage of metamorphosis preceding maturity. At the University of Geneva (UNIGE), Switzerland, the team of the researcher in biology Emi Nagoshi is closely interested in this insect, used as a model organism for the study of circadian rhythms in the animal kingdom. The researcher's group discovered that the main clock of the Drosophila, formed by neurons clustered in various regions ...

LAST 30 PRESS RELEASES:

How your brain decides blame and punishment -- and how it can be changed

Uniquely human brain region enables punishment decisions

Pinpointing punishment

Chapman University publishes research on attractiveness and mating

E-cigarettes: Special issue from Nicotine & Tobacco Research

Placental problems in early pregnancy associated with 5-fold increased risk of OB & fetal disorders

UT study: Invasive brood parasites a threat to native bird species

Criminals acquire guns through social connections

Restoring ocean health

Report: Cancer remains leading cause of death in US Hispanics

Twin study suggests genetic factors contribute to insomnia in adults

To be fragrant or not: Why do some male hairstreak butterflies lack scent organs?

International team discovers natural defense against HIV

Bolivian biodiversity observatory takes its first steps

Choice of college major influences lifetime earnings more than simply getting a degree

Dominant strain of drug-resistant MRSA decreases in hospitals, but persists in community

Synthetic biology needs robust safety mechanisms before real world application

US defense agencies increase investment in federal synthetic biology research

Robots help to map England's only deep-water Marine Conservation Zone

Mayo researchers identify protein -- may predict who will respond to PD-1 immunotherapy for melanoma

How much water do US fracking operations really use?

New approach to mammograms could improve reliability

The influence of citizen science grows despite some resistance

Unlocking secrets of how fossils form

What happens on the molecular level when smog gets into the lungs?

Using ultrasound to clean medical instruments

Platinum and iron oxide working together get the job done

Tiny silica particles could be used to repair damaged teeth, research shows

A quantum lab for everyone

No way? Charity's logo may influence perception of food in package

[Press-News.org] SIRFLOX study presented at ASCO 2015 Annual Meeting
Press-News.org is a service of DragonFly Company. All Rights Reserved.
Issuers of news releases are solely responsible for the accuracy of their content.